chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information was received from a female patient of unknown age via Pfizer, referring to herself. The patient had received PREVNAR 13, and it was not 100 percent effective. The patient's concurrent conditions and concomitant therapies were not provided. On an unknown date , the patient was vaccinated with a dose of pneumococcal vaccine, polyvalent (23-valent) (manufacturer unknown) (lot#, expiration date, frequency, concentration and route were unknown) for prophylaxis. No longer than five weeks after receiving pneumococcal vaccine, polyvalent (23-valent) (manufacturer unknown), the patient got blood test to see if her resistance to pneumonia went up. The patient's entire chart was exactly same after the pneumonia shot. The pneumococcal vaccine, polyvalent (23-valent) (manufacturer unknown) should have had more protection, but did not find anything. The patient stated she was not protected from pneumonia by vaccine, and her titer was low, nothing, no protection. Titer was less than 3. The patient stated the pneumococcal vaccine, polyvalent (23-valent) (manufacturer unknown) shot did not work. The outcome of event was unknown. The causality between event and pneumococcal vaccine, polyvalent (23-valent) (manufacturer unknown) was not provided. Additional information has been requested.
In May, 2000, the pt received his 1st dose of Lymerix and within 1 hour, post vax, the vaccinee felt queazy. His queasiness lasted for 1-2 days and resolved. On 6/9/00 at 12:30, the pt received his 2nd Lymerix and within 40 minutes, post vax, he experienced chills and shaking. These symptoms seemed to be lessening but were unresolved. The most recent information, received on 6/9/00, reports the condition of the vaccinee as unresolved.
Niacin reaction coupled with fever and body aches caused extreme nausea and extreme shivering.
I have a history of low blood pressure and since receiving the vaccine my blood pressure has been elevated and I have also had a chronic headache
15mins wait p/vax- mild muscle ache; devel fever & chills about 1-2 hrs later w/muscle ache on entire body, h/a & dizziness lasting through the evening;
Subsequent to receiving one dose of varicella virus vaccine live the pt developed herpes zoster with a positive DFA for VZV. His rash was described as vesicular with a distribution of many lesions along the trigeminal nerve and involving several dermatomes, including his left face. He also experienced conjunctivitis without corneal lesions and a subjective fever. The pt sought unspecified medical attention and was treated with acyclovir. Two swab specimens used to scrape the base of two vesicles on the child's left face were submitted for PCR analysis. It was reported that one PCR swab specimen was inadequate, while the other specimen was weakly positive for VZV. 5 days post onset the pt recovered from his experience. Follow up information receiving indicated that the second swab specimen was positive for the Oka/Kerck vaccine strain VZV. No further information is available.
This spontaneous prospective pregnancy report was received from a registered nurse referring to a 20 year old female patient who on 12-APR-2013, was vaccinated with a first dose of VARIVAX (Merck) (supplied lot# H018454, expiration date, 09-OCT-2014). Concurrent therapies included HEPATYRIX and diphtheria toxoid, pertussis acellular vaccine (unspecified), tetanus toxoid. No pertinent medical history provided. Registered nurse reported that subsequently after receiving the dose of VARIVAX (Merck), the patient had a positive pregnancy test. The pregnancy outcome was outcome pending. Additional information has been requested.
FACIAL NUMBING AFTER FIRST DOSE, SEIZURE 20 DAYS AFTER SECOND DOSE WHICH WAS ADMINISTERED 5/4/2021
? Pt w/ interesting sequence of events leading up to current main concern of rash following covid vaccine. She had shingles in jan 2020, recovered, then got two doses of Shingrix Aug and Oct 2020 w/o problems, then developed clinically mild covid infection Nov 2020, then  got first dose Moderna Jan 2021 that was followed by a shingles-like rash 10 days following the vaccine. Rash was likely a reactivation of herpes zoster precipitated by the covid vaccine. This has been reported in the literature in case reports. Is is unknown whether she will have recurrence of similar rash following the covid vaccine #2. Other rashes reported w/ covid vaccine #1 were less frequent with the 2nd dose. She currently has anxiety disorder that came on in temporal association with the covid vaccine related rash.  ? Discussed that occurrence of rash cannot be predicted after the next covid vaccine.  ? I recommend getting covid vaccine #2. We agreed that patient needs to work out her anxiety disorder before proceeding w/ covid vaccine #2. She is likely immune having had the infection and one vaccine. Will check ab levels for baseline.  ? Will do VAERS report.
The patient was in his usual state of health when after eating dinner on 9/28/21, he developed sudden onset abdominal pain. For dinner he had tomato soup, an apple, along with bacon, lettuce, soy and mayonnaise. The pain was primarily centered between the epigastrium and left upper quadrant. At the time of onset, the pain was intermittent but very severe, and without radiation. This went on for about 2 hours as he observed these symptoms. He denies having any warning prior to onset. He also denies any history of pain similar to this in the days or weeks leading up to the onset of symptoms. He did not take any medications to try to lessen the pain. After this had gone on without relief, he went to the emergency dept.
Medical Assistant accidentally gave 14 year old patient the J & J vaccine. Hospital Infection Disease Provider Doctor and Pediatrician Doctor were both notified.  Member was instructed to go to hospital if he has serious symptoms such as trouble breathing or shortness of breath.
01:43 PM: client was seating in seat and fainted, was put on the floor on a mat, director POD, EMS and dr present,  Legs elevated on a chair.. V/S:114/74, pls at 45/min and SAT at 99%.            01:47 PM V/S at 125/73 pls at 57/min and SAT at 100%.    At 01 53 PM: client seat on a chair, feel better,, V/S at 102/70, pls at 62/min, and SAT at 97%.   At 01:56 PM, client eating snack and then start feeling dizzy again.  )1 58 PM  : patient lay down flat, 4  lead EKG done, pls at 49/min,, 114/66, Sat at 99%.    At 02:00PM, 12 lead EKG done, Pls at 53/min, 124/80, SAT at 100%.  Doctor  notice ST depression in EKG.  At 02:10 PM, patient feel better,, seat upwright,  02: 22PM: 121/75, PLS at 55/min and SAT at 98%. client in chair and feel good.  At 02 29 PM patient stand up, at 02: 30PM: 115/78, PLS at 66/min and SAT 98%, client is now discharge
Information has been received from a woman through the Pregnancy Registry concerning her approximately 33 year old female friend who in approximately July 2000 was vaccinated with varicella vaccine. Two days after vaccination, the pt became pregnant. Medical attention was sought. Follow-up information from a physician indicated that the 33 year old female pt, with a past history of bronchitis, a 1998 spontaneous vaginal delivery of an 8 pound infant, gestational diabetes, in 200 a spontaneous abortion, a remote history of abnormal Pap smears, normal since without STD's, G3, P1, A1 at 34 6/7 weeks was given the EDC of 04/03/2001, by the LMP consistent with a 17 week scan who presented to labor and delivery for induction. Allergies to medications include penicillin, erythromycin and codeine. Current medication includes prenatal vitamins. The pregnancy was complicated with breast cancer with the left modified radical mastectomy performed on 02/01/2001, revealing poorly differentiated invasive dustal carcinoma with 3.5 cm greatest in diameter and positive lymph nodes. The pt needed chemotherapy two weeks postpartum so the decision was made for an early delivery. It was noted that the left mastectomy was healing well. The pt was GBS positive and will be given clindamycin secondary to allergy to penicillin. The pt desired an epidural for pain control. IV pain medications as needed in early induction. Her breast cancer was stable. She was to received chemotherapy two weeks postpartum. The pt was admitted to the labor and delivery. Sterile vaginal exam revealed a cervix that was fingertip, 2 long and high. A Cytotec induction was begun. Three Cytotec inductions had been placed. The pt had good contraction pattern and Pitocin was started. By mid-afternoon, sterile vaginal exam was 3 long and ballotable. Membranes were ruptured at approx. 3:30pm. The pt progressed through labor well and at 17:21 hr, delivered a 5lb. 8.8oz baby. On postpartum day one, the pt was doing well without complaints. She desired discharge to home. The baby would need to stay an additional day. The pt was discharged home on postpartum day two remaining afebrile meeting all goals. It was noted that the baby was given erythromycin 1 g at 17:25 and vitamin K 1 mg IM. Additional info has been requested.
This spontaneous report as received from a register nurse refers to a 5 months infant, of unknown gender. Medical history and concurrent conditions were not reported. On 25-FEB-2014, the patient was vaccinated with dose 3 of ROTATEQ oral, lot #J007283; expiration date: 27-SEP-2014 (dose and strength were not reported). Secondary and concomitant therapies were not reported. Nurse called and stated that improperly stored ROTATEQ was administered to patient. No adverse effects reported. The nurse reported that vaccine dose received by patient was a vaccine improperly stored as follows: On 13-JAN-2014, ROTATEQ was stored outside of recommended temperatures for 2 hours (2 pm- 4 pm) the temperature recorded was 50 degrees F. On 18-JAN-2014, ROTATEQ was stored outside of recommended temperatures for 2 hours (2 pm - 4 pm) the temperature recorded was 49.1 degrees F. On 10-FEB-2014, ROTATEQ was stored outside of recommended temperatures for 6 hours (12 pm - 6 pm) the temperature recorded was 51.8 degrees F. On 16-FEB-2014, ROTATEQ was stored outside of recommended temperatures for 5 hours (12 pm - 5 pm) the temperature recorded was 51.8 degrees F. On 22-FEB-2014, ROTATEQ was stored outside of recommended temperatures for 4 hours (2 pm - 6 pm) the temperature recorded was 52.7 degrees F. On 09-MAR-2014, ROTATEQ was stored outside of recommended temperatures for 2 hours (12 pm - 10 pm) the temperature recorded was 55.4 degrees F. On 15-MAR-2014, ROTATEQ was stored outside of recommended temperatures for 6 hours (8 am - 2 pm) the temperature recorded was 50 degrees F. On 16-MAR-2014, ROTATEQ was stored outside of recommended temperatures for 20 hours (2 am - 10 pm) the temperature recorded was 64.4 degrees F. On 17-MAR-2014, ROTATEQ the temperature reading on the morning was 64.8 degrees F. The total of hours stored outside of recommended temperatures was 55 hours. This is one of several reports from the same reporter. Additional information has been requested.
5 minutes p/vax pt fainted & fell striking head on chair leg; pt remained unconsious approx 20-30 seconds; pt reamined pale c/o nausea 45 mins p/inject;
11/27/02 client called and stated that on 11/26/02 about one hour after receiving #1 hepatits B vaccine she began having dizziness, muscle aches, and fever of 100 which lasted through the night. Symptoms were resolved by this morning.
Acute chest pain diagnosed with acute myocarditis, symptoms onset acutely on 9/8/21, cardiac CTA done ruled out CAD, pending outpatient cardiac MRI.
Reports paresthesias and subjective sense of "numbess" of R lateral neck, face, R ear and temporal area of scalp within 30 min of vaccine that persisted x 90 min. Also reported transient "numbness" of R anterior thigh that resolved spontaneously after 30 min. No pruritic, urticaria, rash. No mucus membrane symptoms - no conjunctivitis, rhinitis or oral/perioral symptoms. No mucosal swelling or sense of swelling. No respiratory symptoms. No presyncopal symptoms. Vitals: BP 134/87, Pulse 103, sats 100%.
Nausea and stomach upset in the morning. Pepto bismol helped a little but the nausea returned. Took Zofran, nausea fully subsided and did not return.
2 1/2 hrs p/recvd vax c/o of racing heart; pt went to ER; poss allergic reaction; lightheaded;
Tested COVID19 positive; Loss of taste; Loss of smell; Headaches; Fever; Body Aches; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Tested COVID19 positive), AGEUSIA (Loss of taste), ANOSMIA (Loss of smell), HEADACHE (Headaches) and PYREXIA (Fever) in a 31-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 ml. On 29-Jan-2021, the patient experienced COVID-19 (Tested COVID19 positive), AGEUSIA (Loss of taste), ANOSMIA (Loss of smell), HEADACHE (Headaches), PYREXIA (Fever) and MYALGIA (Body Aches). At the time of the report, COVID-19 (Tested COVID19 positive), AGEUSIA (Loss of taste), ANOSMIA (Loss of smell), HEADACHE (Headaches), PYREXIA (Fever) and MYALGIA (Body Aches) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 29-Jan-2021, SARS-CoV-2 test: unknown (Positive) COVID-19 positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications reported by investigator  No treatment medications provided by the reporter.   Patient stated that she is completely fine now but she is under quarantine.
One week after receiving vaccine my left arm became sore again and turned red' The next day it became very red, swollen, sore, warm and very itchy. I saw my PCP on Feb. 24 and showed the vaccine site to her.  She prescribed an antibiotic, Cephalexin, for a 10 day course. She also suggested using an OTC cortizone creme for the itch.
Severe headache, nausea, 100.6 fever, body aches (back area), diarreah, used medical marijuana and Tylenol.
This spontaneous report as received from a healthcare worker refers to an unspecified number of patients of unknown age and gender. On an unknown date the patient were intramuscularly vaccinated with VAQTA (dosage schedule was not reported) which had been improperly stored. No adverse effects reported. This is one of several reports received from the same reporter. Additional information has been requested.
pt recv vax & exp fever, cough, rash, felt poorly;devel sore throat & MD felt had the flu;
coughing, dizziness, 2/19 urgent care, prescribed antibiotic for week (Cefpodoxime)
mom reports fever, runny nose @ 7 days p/MMR: On 3rd day of fever rash appeared in face & spread down to cover entire body; fever d/c p/rash appeared; mom used Caladryl to control itching;
patient developed severe pruritis almost immediately after vaccination then came to our clinic. no hives, no signs of symptoms of anaphylaxis. controlled with high doses of antihistamines.
3 weeks p/vax dizziness, weakness on lt side dx w/multiple sclerosis APR94;
Nnurse was called to assist a patient that had left the monitoring area. Upon arrival, patient was sitting in mall with back leaning on wall. Patient was AAAx3. He was pale and diaphoretic. Patient stated he waited his 15 minutes and felt fine. Patient received dose 1 of Pfizer Covid Vaccine (Lot #EN6207, Exp 5/31/21). When he was walking back to his car he "blacked out" and fell to the floor. Patient stated he hit his head on the ground. No visible injury to back of head was observed. Patient reported he did not eat or drink anything prior to coming. He stated it was warm in the mall and he was having difficulty breathing with the mask on. Patient was instructed to take his mask off. VS were assessed: 98/68, HR 82, pulse ox 98% room air. Patient was given water and some chocolate. Patient stated he started to feel better. Patient was assisted into wheelchair and continued to be observed. Patient stated he initially started to feel better, but then felt lightheaded again. VS reassessed @ 0948 BP 92/64, HR 72, pulse ox 98% room air. This nurse advised patient EMS should be called for further evaluation. Patient refused and stated he did not want to go to the hospital. Nurse again advised that his blood pressure remained low and he should be further evaluated. Patient continued to refuse. Patient was advised to call someone for a ride home as it was advised he should not drive at this time. Patient called his father for transport home. Patient was given a sprite to drink while waiting for his ride. Patient was accompanied by monitor until ride arrived. Patient was picked up and left without further incident.
dies hours after getting Covid-19 vaccine; This is a spontaneous report from a non-contactable consumer (Pfizer-sponsored program). A patient of unspecified age and gender received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection; Lot Number: Unknown), via an unspecified route of administration on an unspecified date as SINGLE DOSE for covid-19 immunization. The patient medical history and concomitant medications were not reported. The patient experienced dies hours after getting covid-19 vaccine on an unspecified date. It was not reported if an autopsy was performed. The outcome of the event was fatal.  No follow-up attempts are Possible; information about batch/ lot number cannot be obtained.; Reported Cause(s) of Death: dies hours after getting Covid-19 vaccine
Pt was given a vaccine on 10/29. On 10/30 she experienced severe pain in her shoulder. After a few days she was seen by her doctor who indicated that vaccine was given in the bursa from her description of the pain. She was treated with oral steroids which did not help to alleviate the pain.  She reports that over time the pain is subsiding, but she is still experiencing pain with ADL. She is consulting with a kinesiologist to aid in movement therapy.
* Syncope episode 10 minutes after inj. * Provided O2 at 8L - x 10 -15 minutes - had pt lay flat. * Continued to complain of headache x 1 hour.
This spontaneous report was received from a Licensed Practical Nurse and refers to a patient of unknown age. No information regarding the patient's medical history, concurrent conditions or concomitant medications was provided. On unknown dates in 2013, the patient received three separate doses of GARDASIL 9 injection (dose, lot number and expiration date were not reported). On 01-AUG-2018, the patient was inadvertently vaccinated with the fourth dose of GARDASIL 9 injection (dose, lot number and expiration date were not reported). No adverse effects were reported.
pt recv vax 16NOV98 1055AM & 11AM had red rash @ site on neck & lower jaw;no other rxn;child cont to jump & play;BP 84/50, P100;
lymph node pain; patient's arm was extremely painful; arm was very very red; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (patient's arm was extremely painful), VACCINATION SITE ERYTHEMA (arm was very very red) and LYMPHADENOPATHY (lymph node pain) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     NO Medical History Information was reported.    On 04-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 01-Feb-2021, the patient experienced VACCINATION SITE PAIN (patient's arm was extremely painful) and VACCINATION SITE ERYTHEMA (arm was very very red). On 06-Feb-2021, the patient experienced LYMPHADENOPATHY (lymph node pain). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency and IBUPROFEN at an unspecified dose and frequency. On 04-Feb-2021, VACCINATION SITE PAIN (patient's arm was extremely painful) and VACCINATION SITE ERYTHEMA (arm was very very red) had resolved. At the time of the report, LYMPHADENOPATHY (lymph node pain) had not resolved. Not Provided          No relevant concomitant medications were reported. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 08-Feb-2021 and was forwarded to Moderna on 08-Feb-2021.    This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (patient's arm was extremely painful), VACCINATION SITE ERYTHEMA (arm was very very red) and LYMPHADENOPATHY (lymph node pain) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     NO Medical History Information was reported.    On 04-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 01-Feb-2021, the patient experienced VACCINATION SITE PAIN (patient's arm was extremely painful) and VACCINATION SITE ERYTHEMA (arm was very very red). On 06-Feb-2021, the patient experienced LYMPHADENOPATHY (lymph node pain). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency and IBUPROFEN at an unspecified dose and frequency. On 04-Feb-2021, VACCINATION SITE PAIN (patient's arm was extremely painful) and VACCINATION SITE ERYTHEMA (arm was very very red) had resolved. At the time of the report, LYMPHADENOPATHY (lymph node pain) had not resolved. Not Provided          No relevant concomitant medications were reported.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of these events, a causal relationship cannot be excluded.
NO ADVERSE EVENT; PNEUMOVAX23 was administered to a patient on 16JUN2021 after experiencing a temperature excursion; This spontaneous report was received from a vaccine coordinator, referring to a patient of unknown age and gender. The patient's historical drugs, medical history, concomitant therapies and concurrent conditions were not reported.  On 16-JUN-2021, the patient was vaccinated with an improper stored dose of Pneumococcal Vaccine, Polyvalent (23-valent) (PNEUMOVAX23) lot# T033369, expiration date 26-MAY-2022, for prophylaxis (strength, dose, route and frequency were not reported).   The temperature excursion was of -40.0 Centigrade degrees (°C), during 45 minutes. A previous temperature excursion was not reported. A digital data logger was involved. No adverse effects were reported. combinationproductreport: Yes; brandname: PNEUMOVAX23 SYRINGE (DEVICE); commondevicename: Pneumococcal Vaccine, Polyvalent (23-valent); productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: T033369; expirationdate: 26-MAY-2022; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet criteria for reportability
One day post vax the pt experienced numbness, redness, swelling and pain in the bottom of the left foot. The swelling included all of the toes. The most recent information received, reports the condition of the pt is getting worse.